Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Interferon Alfa 2B

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    20 result(s) found for: Interferon Alfa 2B. Displaying page 1 of 1.
    EudraCT Number: 2008-000706-36 Sponsor Protocol Number: P05498 Start Date*: 2008-09-30
    Sponsor Name:Hannover Medical School; Competence Network Viral Hepatitis (Hep-Net)
    Full Title: Optimization of treatment for patients with chronic hepatitis C infected with HCV-genotype 2 or 3: 12 vs. 24 weeks of treatment extension for patients without rapid virological response
    Medical condition: chronic hepatitis c infection genotype 2/3
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004862 10008914 Chronic hepatitis C without mention of hepatic coma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-000867-24 Sponsor Protocol Number: ALFR-HC-04 Start Date*: 2005-05-23
    Sponsor Name:Human Genome Sciences, Inc.
    Full Title: A PHASE 2b, RANDOMIZED, MULTI-CENTER, ACTIVE-CONTROLLED, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ALBUFERON (RECOMBINANT HUMAN ALBUMIN-INTERFERON ALFA FUSION PROTEIN) IN COMBINATION...
    Medical condition: Hepatitis type C chronic
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2009-012459-96 Sponsor Protocol Number: CIN-VHC-01 Start Date*: 2010-06-08
    Sponsor Name:Dr Calleja Panero
    Full Title: VALORACIÓN INTENSIVA DE LA CINÉTICA DEL RNA DEL VIRUS DE LA HEPATITIS C COMO PREDICTOR PRECOZ DE AUSENCIA DE RESPUESTA VIROLÓGICA SOSTENIDA EN PACIENTES CON HEPATITIS CRÓNICA POR VHC TRATADOS CON I...
    Medical condition: HEPATITIS C
    Disease: Version SOC Term Classification Code Term Level
    9 10008912 Chronic hepatitis C LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-012010-52 Sponsor Protocol Number: mRCC Start Date*: 2009-08-04
    Sponsor Name:Department of Oncology, Aarhus University Hospital
    Full Title: Bevacizumab, Interleukin-2 and Interferon-alpha in metastathic renal cell carcinoma
    Medical condition: Patient with previously untreated Metastatic Renal Cell Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050513 Metastatic renal cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2006-002704-34 Sponsor Protocol Number: HGS1008-C1067 Start Date*: 2007-04-27
    Sponsor Name:Human Genome Sciences, Inc.
    Full Title: A Phase 3, Randomized, Multi-Center Study to Evaluate the Efficacy and Safety of Albumin Interferon Alfa-2b (alb-IFN) in Combination with Ribavirin Compared with Peginterferon Alfa-2a (PEGASYS or P...
    Medical condition: Chronic Hepatitis C (CHC) genotype 2/3.
    Disease: Version SOC Term Classification Code Term Level
    8.0 10008912 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FR (Completed) SE (Completed) GB (Completed) DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2008-001260-36 Sponsor Protocol Number: MEN-TOS Start Date*: 2008-03-04
    Sponsor Name:AZIENDA OSPEDALIERA POLICLINICO DI MODENA
    Full Title: Terapia PEG-Interferone alfa 2B+Ribavirina versus terapia PEG-Interferone alfa 2B + Ribavirina+ Terapia ormonale sostitutiva (TOS) nella prevenzione della progressione della fibrosi epatica nell’ep...
    Medical condition: Women in post-menopause with Chronic HCV positive hepatitis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019805 Hepatobiliary disorders SOC
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-002703-13 Sponsor Protocol Number: HGS1008-C1060 Start Date*: 2007-03-20
    Sponsor Name:Human Genome Sciences, Inc.
    Full Title: A Phase 3, Randomized, Multi-Center Study to Evaluate the Efficacy and Safety of Albumin Interferon Alfa-2b (alb-IFN) in Combination with Ribavirin Compared with Peginterferon Alfa-2a (PEGASYS or P...
    Medical condition: Chronic hepatitis C (CHC) genotype 1.
    Disease: Version SOC Term Classification Code Term Level
    8.0 10008912 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) AT (Completed) FR (Completed) GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2008-002039-34 Sponsor Protocol Number: CABF656B2202 Start Date*: 2008-12-15
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open-label, randomized, multicenter, active-controlled, dose-ranging study to evaluate the safety and efficacy of albinterferon alfa-2b administered every 4 weeks plus ribavirin in interferon al...
    Medical condition: chronic hepatitis C
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008912 Chronic hepatitis C LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) FR (Completed) PL (Completed) IT (Completed) GR (Prematurely Ended) GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-001485-15 Sponsor Protocol Number: MYR204 Start Date*: 2019-09-24
    Sponsor Name:Gilead Sciences Inc.
    Full Title: A Multicenter, Open-label, Randomized Phase 2b Clinical Study to Assess Efficacy and Safety of Bulevirtide in Combination with Pegylated Interferon alfa-2a in Patients with Chronic Hepatitis Delta
    Medical condition: Chronic Hepatitis Delta
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10019763 Hepatitis delta LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-001030-94 Sponsor Protocol Number: KKS-227 Start Date*: 2017-03-29
    Sponsor Name:Philipps University Marburg
    Full Title: Efficacy and safety of pegylated-proline-interferon alpha 2B (AOP2014) in maintaining deep molecular remissions in patients with chronic myeloid leukemia (CML) who discontinue ABL-kinase inhibitory...
    Medical condition: Chronic myeloid leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10009016 Chronic myeloid leukemia in remission LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-021716-42 Sponsor Protocol Number: 1220.30 Start Date*: 2011-03-11
    Sponsor Name:Boehringer Ingelheim International GmbH
    Full Title: A phase III, randomised, double-blind and placebo-controlled study of once daily BI 201335 120 mg for 12 or 24 weeks or BI 201335 240 mg for 12 weeks in combination with pegylated interferon-α and ...
    Medical condition: genotype 1 chronic hepatitis C infection
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10019744 Hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) BE (Completed) GB (Completed) DE (Completed) ES (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2004-000820-34 Sponsor Protocol Number: P03548 Start Date*: 2006-08-31
    Sponsor Name:Integrated Therapeutics Group, Incorporated-a subsidiary of Schering Plough
    Full Title: Comparison of Three Regimens of PEG-Intron plus Ribavirin in the Treatment of Chronic Hepatitis C, Genotype 2 or 3, in Previously Untreated Patients
    Medical condition: Chronic Hepatitis C, Genotype 2 or 3
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed)
    Trial results: View results
    EudraCT Number: 2010-021734-59 Sponsor Protocol Number: 1220.19 Start Date*: 2011-08-11
    Sponsor Name:Boehringer Ingelheim Limited
    Full Title: Safety and Efficacy of 240 mg BI 201335 once daily in combination with pegylated interferon alpha 2a and ribavirin for treatment of chronic Hepatitis C (HCV) genotype 1 infection in HIV/HCV-co-in...
    Medical condition: Chronic hepatitis C infection genotype 1 in patients coinfected with HIV-1
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10019744 Hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) DE (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-015121-37 Sponsor Protocol Number: ANRS HC 23 Start Date*: 2009-12-10
    Sponsor Name:ANRS
    Full Title: Etude multicentrique randomisée ouverte comparant la réduction virale et la tolérance de l’association IFN alpha-2b XL + ribavirine versus IFN peg alpha-2b + ribavirine chez des patients atteints d...
    Medical condition: Evaluation de l’activité antivirale d’injections hebdomadaires d’un nouvel interféron α-2b à libération prolongée formulé avec Medusa® (IFNα-2bXL) chez des patients atteints d’hépatite chronique v...
    Disease: Version SOC Term Classification Code Term Level
    12.0 10008912 Chronic hepatitis C LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2010-021715-17 Sponsor Protocol Number: 1220.7 Start Date*: 2011-07-12
    Sponsor Name:Boehringer Ingelheim Limited
    Full Title: A phase III, randomised, double-blind and placebo controlled study of once daily BI 201335, 240 mg for 12 or 24 weeks in combination with pegylated interferon-α and ribavirin in patients with genot...
    Medical condition: Chronic hepatitis C infection genotype 1
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10019744 Hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) PT (Completed) BE (Completed) DE (Completed) AT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2008-001283-37 Sponsor Protocol Number: GE-ARNICA-2008 Start Date*: 2007-09-24
    Sponsor Name:AZIENDA OSPEDALIERA SPEDALI CIVILI DI BRESCIA
    Full Title: Chronic hepatitis C in illicit drug users and the role of antiviral therapy: the ARNICA project (Antiviral tReatment for chroNic hepatItis C in Active substance users)
    Medical condition: Chronic Hepatitis C
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019715 Hepatic viral infections HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-004527-31 Sponsor Protocol Number: GS-US-196-0103 Start Date*: 2008-12-12
    Sponsor Name:Gilead Sciences Incorporated
    Full Title: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Comparing 24 or 48 Weeks of GS-9190, in Combination with Peginterferon Alfa 2a and Ribavirin, to 48 Weeks of Peginterferon Alfa 2a and...
    Medical condition: Genotype-1 Chronic Hepatitis C Virus (HCV) Infection
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008912 Chronic hepatitis C LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IE (Completed) GB (Completed) DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2010-024557-36 Sponsor Protocol Number: VHCRP1007 Start Date*: 2012-05-29
    Sponsor Name:The Kirby Institute
    Full Title: A phase IV open-label multicentre, international trial of response guided treatment with directly observed pegylated interferon alfa 2b and self-administered ribavirin for patients with chronic HCV...
    Medical condition: Chronic Hepatitis C genotype 2 and 3 infection.
    Disease: Version SOC Term Classification Code Term Level
    18.0 10021881 - Infections and infestations 10008912 Chronic hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-020911-35 Sponsor Protocol Number: GS-US-196-0123 Start Date*: 2011-01-17
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating 16 and 24 Weeks of Response Guided Therapy With GS-9190, GS-9256, Ribavirin (Copegus®) and Peginterferon Alfa 2a (Pegasys®)...
    Medical condition: Chronic Hepatitis C Virus Infection
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021881 - Infections and infestations 10008912 Chronic hepatitis C LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) DE (Completed) GB (Prematurely Ended) BE (Prematurely Ended) AT (Completed) PL (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-000292-42 Sponsor Protocol Number: TPL108390 Start Date*: 2007-12-06
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: ENABLE 2 (Eltrombopag to INitiate and Maintain Interferon Antiviral Treatment to Benefit Subjects with Hepatitis C related Liver DiseasE) Randomised, placebo-controlled, multi-centre study to asses...
    Medical condition: Thrombocytopenic subjects with hepatitis C viral infection
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019744 Hepatitis C LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) GR (Completed) BE (Completed) ES (Completed) IT (Completed) CZ (Completed) SK (Completed) NL (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 00:20:47 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA